Tang Ying, Zhao Shunfeng, Wang Jiliang, Li Dongfeng, Ren Qingbo, Tang Yurong
Zaozhuang Hospital of Zaozhuang Mining Group, NO.188 Shengli Road, Zaozhuang, 277101, People's Republic of China.
The Third People's Hospital of Liaocheng, No. 62 Weiyu Road, Liaocheng, 252000, People's Republic of China.
Neurol Sci. 2017 Jun;38(6):1087-1092. doi: 10.1007/s10072-017-2912-y. Epub 2017 Apr 3.
Gliomas are the most common and aggressive brain tumors, and a poor prognosis is correlated with its World Health Organization (WHO) grade. MicroRNAs (miRNAs) may serve as diagnostic and prognostic biomarkers in gliomas. In the present study, we collected plasma samples from patients with gliomas to evaluate the expression of miR-122 and analyzed the role of miR-122 in the diagnosis and prognosis of gliomas. We found that the expression of miR-122 in the plasma of patients with gliomas was significantly down-regulated compared to that in healthy individuals. In addition, the expression of miR-122, which was significantly correlated with WHO grade, decreased along with the development of gliomas. A receiver operating characteristic curve analysis showed high sensitivity and specificity of miR-122 for diagnosing gliomas (sensitivity 91.9%; specificity 81.1%; area under the curve 0.939). Finally, we found that lower expression of miR-122 was correlated with poor prognosis, and miR-122 was an independent prognostic parameter indicating poor prognosis for gliomas. In conclusion, our results showed that plasma miR-122 expression might act as a diagnostic and prognostic biomarker for gliomas.
胶质瘤是最常见且侵袭性最强的脑肿瘤,其预后不良与世界卫生组织(WHO)分级相关。微小RNA(miRNA)可能作为胶质瘤的诊断和预后生物标志物。在本研究中,我们收集了胶质瘤患者的血浆样本以评估miR-122的表达,并分析miR-122在胶质瘤诊断和预后中的作用。我们发现,与健康个体相比,胶质瘤患者血浆中miR-122的表达显著下调。此外,miR-122的表达与WHO分级显著相关,并随着胶质瘤的发展而降低。受试者工作特征曲线分析显示,miR-122对胶质瘤诊断具有较高的敏感性和特异性(敏感性91.9%;特异性81.1%;曲线下面积0.939)。最后,我们发现miR-122表达较低与预后不良相关,且miR-122是提示胶质瘤预后不良的独立预后参数。总之,我们的结果表明血浆miR-122表达可能作为胶质瘤的诊断和预后生物标志物。